Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Issued (2016 - 2025)

Lineage Cell Therapeutics' Shares Issued history spans 16 years, with the latest figure at $931000.0 for Q4 2025.

  • For Q4 2025, Shares Issued changed N/A year-over-year to $931000.0; the TTM value through Dec 2025 reached $1.2 million, changed N/A, while the annual FY2025 figure was $1.2 million, N/A changed from the prior year.
  • Shares Issued reached $931000.0 in Q4 2025 per LCTX's latest filing, up from $319000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $33.1 million in Q2 2021 to a low of -$5.7 million in Q3 2023.
  • Average Shares Issued over 5 years is $5.8 million, with a median of $232500.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: plummeted 99.99% in 2022, then surged 3830.14% in 2023.
  • A 5-year view of Shares Issued shows it stood at $24.6 million in 2021, then plummeted by 99.41% to $146000.0 in 2022, then crashed by 4004.79% to -$5.7 million in 2023, then soared by 96.16% to -$219000.0 in 2024, then skyrocketed by 525.11% to $931000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Shares Issued are $931000.0 (Q4 2025), $319000.0 (Q3 2025), and -$219000.0 (Q3 2024).